They might not participate in huge numbers if Covaxin is used, the resident doctors of Ram Manohar Lohia Hospital said in a letter.
Resident doctors at the Ram Manohar Lohia Hospital, one of Delhi’s biggest healthcare hubs, today demanded they be administered Covishield vaccine and not Covaxin since the former has completed all three stages of trials as required under the protocol. The Covaxin produced by Hyderabad-based Bharat Biotech is still only undergoing stage-III trials. However, the centre has sought to underplay such apprehensions and said “a lot of work” had gone into the development of both products.
They might not participate in huge numbers if Covaxin is used, the resident doctors of Ram Manohar Lohia Hospital said in a letter.
“Covaxin manufactured by Bharat Biotech is being preferred over Covishield manufactured by Serum Institute in our hospital…We would like to bring to your notice that the residents are a bit apprehensive about the lack of complete trial in the case of Covaxin and might not participate in huge numbers thus defeating the purpose of the vaccination,” the resident doctors said in their letter to the medical superintendent of the facility.
“We request you to vaccinate us with Covishield which has completed all stages of the trial before its rollout,” the letter further added.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
